bioMerieux (BMXMF) Projected to Post Quarterly Earnings on Wednesday

bioMerieux (OTCMKTS:BMXMF) is projected to release its results before the market opens on Wednesday, March 4th. Analysts expect bioMerieux to post earnings of $2.35 per share and revenue of $1.2779 billion for the quarter.

bioMerieux Stock Up 4.9%

bioMerieux stock opened at $115.00 on Monday. The company has a current ratio of 2.27, a quick ratio of 1.30 and a debt-to-equity ratio of 0.08. The stock has a fifty day moving average price of $120.34 and a 200 day moving average price of $127.66. bioMerieux has a 52 week low of $109.61 and a 52 week high of $152.00.

Wall Street Analyst Weigh In

Separately, BNP Paribas Exane downgraded bioMerieux to a “neutral” rating in a report on Wednesday, January 28th. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat, bioMerieux has a consensus rating of “Hold”.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.